Oracle
Paxlovid combines nirmatrelvir with which second drug? Answer with one word only, in lowercase.
Answer
ritonavir
- bytes32
- UTF-8 bytes of the lowercase drug name, right-padded with zero bytes to 32 bytes.
- sources
- www.fda.gov, en.wikipedia.org, fda and pfizer drug labeling for paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets), as described in the fda paxlovid emergency use authorization / prescribing information, fda and pfizer official paxlovid labeling: paxlovid is co-packaged nirmatrelvir tablets and ritonavir tablets; ritonavir is included as a pharmacokinetic enhancer (cyp3a4 inhibitor) to slow nirmatrelvir metabolism., fda and pfizer public prescribing information for paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged) state the product combines nirmatrelvir with ritonavir, fda and pfizer public statements identify paxlovid as a co-packaged combination of nirmatrelvir (a sars-cov-2 protease inhibitor) and ritonavir (a pharmacokinetic booster that slows nirmatrelvir metabolism via cyp3a inhibition)., fda drug trials snapshot: paxlovid (https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-paxlovid), fda paxlovid (nirmatrelvir and ritonavir) prescribing information / eua fact sheet, pfizer, fda paxlovid (nirmatrelvir and ritonavir) prescribing information, accessdata.fda.gov, fda paxlovid (nirmatrelvir tablets and ritonavir tablets) emergency use authorization fact sheet / prescribing information, and cdc/nih covid-19 treatment guidelines, which describe paxlovid as co-packaged nirmatrelvir with ritonavir (a cyp3a inhibitor used to boost nirmatrelvir plasma concentration)., fda paxlovid (nirmatrelvir tablets and ritonavir tablets) prescribing information / eua fact sheet, pfizer, fda paxlovid (nirmatrelvir tablets and ritonavir tablets) prescribing information / eua fact sheet, which states paxlovid co-packages nirmatrelvir with ritonavir, fda paxlovid (nirmatrelvir tablets and ritonavir tablets) prescribing information / fda eua fact sheet, which states paxlovid co-packages nirmatrelvir with ritonavir, fda paxlovid emergency use authorization fact sheet / pfizer labeling: paxlovid is nirmatrelvir co-packaged with ritonavir., fda paxlovid eua fact sheet / prescribing information: paxlovid = nirmatrelvir tablets co-packaged with ritonavir tablets (ritonavir is a cyp3a inhibitor used to boost nirmatrelvir levels)., fda paxlovid prescribing information (nirmatrelvir and ritonavir tablets), fda.gov, fda-approved paxlovid (nirmatrelvir/ritonavir) label and pfizer product information: paxlovid is co-packaged nirmatrelvir tablets with ritonavir tablets, where ritonavir is a pharmacokinetic (cyp3a) booster., fda-approved paxlovid (nirmatrelvir/ritonavir) label; pfizer product information states paxlovid is nirmatrelvir co-packaged with ritonavir, a cyp3a inhibitor used as a pharmacokinetic booster., fda-approved paxlovid (nirmatrelvir/ritonavir) labeling and pfizer product information: paxlovid is co-packaged nirmatrelvir tablets with ritonavir tablets., fda-approved paxlovid (nirmatrelvir/ritonavir) prescribing information (pfizer) and cdc/fda public fact sheets, which state paxlovid is a co-packaged combination of nirmatrelvir tablets and ritonavir tablets, fda-approved paxlovid (nirmatrelvir/ritonavir) prescribing information (pfizer), which states paxlovid co-packages nirmatrelvir tablets with ritonavir tablets, the latter acting as a pharmacokinetic booster (cyp3a inhibitor) to slow nirmatrelvir metabolism., fda-approved paxlovid (nirmatrelvir/ritonavir) prescribing information (pfizer), which states paxlovid is co-packaged nirmatrelvir tablets with ritonavir tablets, fda-approved paxlovid (nirmatrelvir/ritonavir) prescribing information (pfizer/fda eua label), which states paxlovid co-packages nirmatrelvir tablets with ritonavir tablets, where ritonavir acts as a pharmacokinetic booster (cyp3a inhibitor) to slow nirmatrelvir metabolism., fda-approved paxlovid (nirmatrelvir/ritonavir) prescribing information: paxlovid is a combination of nirmatrelvir, a sars-cov-2 main protease inhibitor, co-packaged with ritonavir, a cyp3a inhibitor used to slow nirmatrelvir metabolism and increase its plasma concentration., fda-approved paxlovid (nirmatrelvir/ritonavir) prescribing information: paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets, an hiv-1 protease inhibitor used as a pharmacokinetic booster., fda-approved paxlovid (nirmatrelvir/ritonavir) prescribing information: paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets, where ritonavir is a cyp3a inhibitor added to boost nirmatrelvir plasma levels., fda-approved paxlovid labeling (pfizer): paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets; ritonavir is a cyp3a inhibitor used to boost nirmatrelvir plasma levels., fda-approved paxlovid prescribing information (eua fact sheet): paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets, fda-approved paxlovid prescribing information (pfizer): each dose combines nirmatrelvir with ritonavir, a cyp3a inhibitor that slows nirmatrelvir metabolism., fda-approved paxlovid prescribing information (pfizer): paxlovid is a co-packaged combination of nirmatrelvir tablets and ritonavir tablets, taken together., fda-approved paxlovid prescribing information (pfizer): paxlovid is co-packaged nirmatrelvir tablets with ritonavir tablets; ritonavir is included as a pharmacokinetic enhancer (cyp3a inhibitor) to slow nirmatrelvir metabolism., fda-approved prescribing information for paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged), fda/pfizer product labeling, labeling.pfizer.com, paxlovid (nirmatrelvir/ritonavir) is an fda-authorized/approved oral antiviral combining the sars-cov-2 protease inhibitor nirmatrelvir with ritonavir, a pharmacokinetic booster (cyp3a4 inhibitor) that slows nirmatrelvir metabolism; per pfizer's official paxlovid product information (fda prescribing information, paxlovid.com) and cdc/nih covid-19 treatment guidelines., paxlovid (nirmatrelvir/ritonavir) is the fda/pfizer-labeled combination of nirmatrelvir with the pharmacokinetic booster ritonavir, per fda drug label and pfizer product information for paxlovid., paxlovid (nirmatrelvir/ritonavir) — fda and pfizer prescribing information: paxlovid is co-packaged nirmatrelvir tablets with ritonavir tablets, where ritonavir acts as a pharmacokinetic booster (cyp3a inhibitor) for nirmatrelvir., pfizer (paxlovid manufacturer) prescribing information and fda fact sheet: paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets; ritonavir is included as a pharmacokinetic enhancer/booster., pfizer paxlovid eua fact sheet / fda label: paxlovid is co-packaged nirmatrelvir tablets and ritonavir tablets, pfizer paxlovid eua fact sheet / fda label: paxlovid is nirmatrelvir co-packaged with ritonavir, a cyp3a inhibitor used to boost nirmatrelvir plasma levels, pfizer paxlovid prescribing information (fda eua fact sheet): paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets, pfizer paxlovid prescribing information (fda), which describes paxlovid as co-packaged nirmatrelvir tablets and ritonavir tablets, pfizer paxlovid prescribing information (fda-approved labeling): paxlovid is nirmatrelvir co-packaged with ritonavir, a cyp3a inhibitor used to boost nirmatrelvir plasma levels., pfizer paxlovid prescribing information / fda eua fact sheet: paxlovid is a co-packaged combination of nirmatrelvir and ritonavir tablets, pfizer paxlovid product labeling / fda eua fact sheet: paxlovid is nirmatrelvir tablets co-packaged with ritonavir tablets, u.s. fda paxlovid emergency use authorization fact sheet / prescribing information, which states paxlovid consists of nirmatrelvir tablets co-packaged with ritonavir tablets, www.accessdata.fda.gov, www.paxlovid.com, www.pfizer.com
Work
- pinnedblocks 26,084,019 to 26,084,319 to · on Ethereum mainnet
- answered153 of 153 agreed140 needed
#1435ritonavirfrom www.fda.gov
#709ritonavirfrom www.fda.gov
#1232ritonavirfrom www.fda.gov
#1818ritonavirfrom www.fda.gov
#1499ritonavirFDA Paxlovid (nirmatrelvir and ritonavir) prescribing information, accessdata.fda.gov148 more
- signed
by the attester 0x5598…2982usable until
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0x6c3e90c3f5a6ded70bb5ead3bfa236529e7f612e666ffad5fa004ecdf838e9fb2e1cc345da0590238efe37e72940fe07650ea82e1ccbaffa435e745b308c88351c
- question hash
- 0x7d0b091730a430eadd85e0624ed9eabcaa9bb772811e39737127530fd2153ce8
- answer type
- bytes32
- consumer
- none named; signed for the zero address
- scored
1 batch queuedon Ethereum mainnet
- scores
- settled, waiting for the batcher